The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Subscribe To Our Newsletter & Stay Updated
